Sequenom Laboratories Expands International Noninvasive Prenatal Testing Services To Broader Population With VisibiliT™ Test
PR Newswire Association LLC |
"This is an important development because it makes an excellent test much more affordable and accessible to a wider spectrum of pregnant women throughout the world," said Professor
Performance of the VisibiliT test was determined by a clinical evaluation study of over 1,000 samples, and demonstrated a greater than 99% sensitivity and specificity for trisomies 21 and 18. A poster entitled, 'Application of risk-score analysis to low-coverage whole genome sequencing data for the noninvasive detection of trisomy 21 and trisomy 18,' will be presented at the 18th
Building a global portfolio of laboratory-developed tests for noninvasive prenatal assessment
"The launch of the VisibiliT test is an important achievement for the company, as we are expanding our noninvasive prenatal testing menu to provide additional choices to better serve the broader prenatal testing community," said
The VisibiliT test will be available to international markets beginning in August.
The technology at the forefront of prenatal testing
Using a maternal blood sample, the VisibiliT and MaterniT21 PLUS tests analyze chromosomal material in cell-free fetal DNA of pregnant women. The VisibiliT test reports a risk score for common fetal chromosomal abnormalities, specifically trisomies 21 and 18, as well as fetal gender. The MaterniT21 PLUS test, by contrast, reports both common and rare fetal chromosomal abnormalities—from trisomies 21, 18 and 13 to fetal sex aneuploidies, trisomies 16, 22, fetal gender and select microdeletions.
Both tests were developed, validated and are performed exclusively by
Sequenom Laboratories Presentations at ISPD
11:06-11:16 a.m. – NIPT 2.0: Identification of 22q microdeletions by noninvasive prenatal testing; Presenter:Juan-Sebastian Saldivar - 11:39 –
11:45 a.m. – Genome wide analysis of sub-chromosomal copy number variations using NIPT in over 4500 patients; Presenter:Dirk van den Boom
Sequenom Scientific Posters at ISPD
- Characterization and targeted isolation of circulating cell-free DNA for the noninvasive prenatal MaterniT21™ PLUS LDT
- Noninvasive detection of a balanced fetal translocation from maternal plasma
- Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma
- Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing
- Evaluation of targeted methodologies for the noninvasive detection of fetal aneuploidies
- Prenatal detection of fetal aneuploidy on the Ion Torrent proton platform
- Application of risk score analysis to low-coverage whole genome sequencing data for the noninvasive detection of trisomy 21 and trisomy 18
About
About
SEQUENOM®, HerediT™, MaterniT21™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, are trademarks of
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
SOURCE
Wordcount: | 1251 |
OSSAA legal costs spark criticism
CollegeAdvantage Renews 529 Contract with BlackRock, Reduces Customer Fees and Adds Investment Options
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News